Upstream Bio, Inc. (UPB) Stock Analysis

Upstream Bio, Inc. (UPB) is a publicly traded company in the HEALTHCARE sector. It trades at $7.25, carries a market capitalization of $439.71M. This page summarizes the public market data, fundamentals, and frequently asked questions for UPB, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Upstream Bio, Inc. currently has a Neutral sentiment score of 0.04.

About Upstream Bio, Inc.

Upstream Bio, Inc. is a clinical-stage biotechnology firm based in Waltham, Massachusetts, dedicated to the advancement of innovative therapies for inflammatory diseases, with a particular emphasis on severe respiratory disorders. The company leverages cutting-edge research and development to address unmet medical needs in this specialty area. With a robust pipeline of therapeutic candidates, Upstream Bio is poised to make significant contributions to the treatment landscape for patients stru...

GNG Research Analysis

GNG Research scores Upstream Bio, Inc. (UPB) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for UPB.

Frequently Asked Questions

Does UPB pay dividends?

Upstream Bio, Inc. (UPB) does not currently pay a regular dividend.

What is UPB's market cap?

Upstream Bio, Inc. (UPB) has a market capitalization of $439.71M with a current stock price of $7.25.